Loading...

We've got a brand new version of Simply Wall St! Try it out

RMMI

CNSX:RMMI
Snowflake Description

Mediocre balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RMMI
CNSX
CA$8M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

RMMI Corp., a development stage company, focuses on the cultivation, production, and sale of medical marijuana products in various forms. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
RMMI Share Price and Events
7 Day Returns
0%
CNSX:RMMI
-0.2%
CA Pharmaceuticals
1.2%
CA Market
1 Year Returns
-
CNSX:RMMI
-45.8%
CA Pharmaceuticals
-0.4%
CA Market
RMMI Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
RMMI (RMMI) 0% -26.3% -37.2% - - -
CA Pharmaceuticals -0.2% -1.8% -21.5% -45.8% 251% 334.4%
CA Market 1.2% 3.3% 0.8% -0.4% 7.4% 4.5%
1 Year Return vs Industry and Market
  • No trading data on RMMI.
  • No trading data on RMMI.
Price Volatility
Industry
5yr Volatility vs Market

RMMI Value

 Is RMMI undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for RMMI. This is due to cash flow or dividend data being unavailable. The share price is CA$0.59.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for RMMI's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are RMMI's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:RMMI PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-0.14
CNSX:RMMI Share Price ** CNSX (2019-09-13) in CAD CA$0.59
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 18.72x
Canada Market PE Ratio Median Figure of 540 Publicly-Listed Companies 14.11x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of RMMI.

CNSX:RMMI PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:RMMI Share Price ÷ EPS (both in CAD)

= 0.59 ÷ -0.14

-4.32x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RMMI is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • RMMI is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does RMMI's expected growth come at a high price?
Raw Data
CNSX:RMMI PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.32x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.57x
Canada Market PEG Ratio Median Figure of 246 Publicly-Listed Companies 0.95x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for RMMI, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on RMMI's assets?
Raw Data
CNSX:RMMI PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$0.50
CNSX:RMMI Share Price * CNSX (2019-09-13) in CAD CA$0.59
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.32x
Canada Market PB Ratio Median Figure of 2,454 Publicly-Listed Companies 1.44x
CNSX:RMMI PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:RMMI Share Price ÷ Book Value per Share (both in CAD)

= 0.59 ÷ 0.50

1.17x

* Primary Listing of RMMI.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • RMMI is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess RMMI's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. RMMI has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RMMI Future Performance

 How is RMMI expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as RMMI has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
110.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is RMMI expected to grow at an attractive rate?
  • Unable to compare RMMI's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare RMMI's earnings growth to the Canada market average as no estimate data is available.
  • Unable to compare RMMI's revenue growth to the Canada market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
CNSX:RMMI Future Growth Rates Data Sources
Data Point Source Value (per year)
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 110.6%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 58.6%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.8%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:RMMI Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:RMMI Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 -1 -2
2019-03-31 -2 -2
2018-12-31 -1 -2
2018-09-30 -1 -1
2018-06-30 -1 -1
2018-03-31 -1 -1
2017-12-31 0 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if RMMI is high growth as no earnings estimate data is available.
  • Unable to determine if RMMI is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:RMMI Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from RMMI Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:RMMI Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -0.14
2019-03-31 -0.14
2018-12-31 -0.14
2018-09-30 -0.14
2018-06-30 -0.10
2018-03-31 -0.10
2017-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if RMMI will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of RMMI’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. RMMI's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. RMMI's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess RMMI's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
RMMI has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RMMI Past Performance

  How has RMMI performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare RMMI's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • RMMI does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare RMMI's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare RMMI's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
RMMI's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from RMMI Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:RMMI Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 -1.80 1.39
2019-03-31 -1.78 1.38
2018-12-31 -1.70 1.32
2018-09-30 -1.44 1.09
2018-06-30 -0.95 0.95
2018-03-31 -0.75 0.75
2017-12-31 -0.56 0.56

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if RMMI has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if RMMI has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if RMMI improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess RMMI's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
RMMI has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RMMI Health

 How is RMMI's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up RMMI's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • RMMI is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • RMMI has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of RMMI's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are -298.8x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from RMMI Company Filings, last reported 2 months ago.

CNSX:RMMI Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 6.84 0.00 1.72
2019-03-31 7.13 0.00 3.70
2018-12-31 7.46 0.00 5.38
2018-09-30 7.84 0.00 6.47
2018-06-30 4.55 0.00 3.20
2018-03-31 4.78 0.00 3.76
2017-12-31 2.48 0.00 2.39
  • RMMI's level of debt (-0.1%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if RMMI's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • RMMI has less than a year of cash runway based on current free cash flow.
  • RMMI has less than a year of cash runway if free cash flow continues to grow at historical rates of 118.1% each year.
X
Financial health checks
We assess RMMI's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. RMMI has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RMMI Dividends

 What is RMMI's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from RMMI dividends.
If you bought CA$2,000 of RMMI shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate RMMI's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate RMMI's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:RMMI Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.2%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as RMMI has not reported any payouts.
  • Unable to verify if RMMI's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of RMMI's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as RMMI has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess RMMI's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can RMMI afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. RMMI has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RMMI Management

 What is the CEO of RMMI's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Earl Connors
COMPENSATION CA$77,500
TENURE AS CEO 1.6 years
CEO Bio

Mr. Earl Connors, B.Sc., P.Eng., MBA has been the President & CEO of RMMI Corp. since February 13, 2018 and its Chairman and Director since February 6, 2018. Mr. Connors is the founder of RMMI. Prior to founding the Corporation, Mr. Connors served as the CEO to a number of private companies and acted as a as an independent consultant to CEO groups. From June 2014 to June 2015, Mr. Connors also consulted to Benchmark Labs, whose business was to apply for LP Status under Healthy Canada’s MMPR for their clients. From July 2015 to June 2016, Mr. Connors acted as CEO of TheraCann, which was the rebranding name chosen for Benchmark Labs. From November 2012 to September 2013, he was CEO of Stimline Services, North America. Mr. Connors is a Professional Engineer registered with the Association of Professional Engineers, Geoscientists of Alberta. He holds a Master of Business Administration from the Haskayne School of Business from the University of Calgary and a degree in Mechanical Engineering from the University of Alberta.

CEO Compensation
  • Earl's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Earl's remuneration is lower than average for companies of similar size in Canada.
Management Team

Earl Connors

TITLE
Chairman
COMPENSATION
CA$78K
TENURE
1.6 yrs

Peter Cheung

TITLE
Chief Financial Officer
COMPENSATION
CA$39K
TENURE
1.8 yrs

Surinder Singh

TITLE
Chief Scientist

Morgan Dakin

TITLE
Manager of Administrative Services
Board of Directors Tenure

Average tenure of the RMMI board of directors in years:

1.6
Average Tenure
  • The average tenure for the RMMI board of directors is less than 3 years, this suggests a new board.
Board of Directors

Earl Connors

TITLE
Chairman
COMPENSATION
CA$78K
TENURE
1.6 yrs

Dave Guebert

TITLE
Director
TENURE
1.6 yrs

Tony Fairfield

TITLE
Director
TENURE
1.6 yrs

Eugene Chen

TITLE
Director
AGE
51
TENURE
1.6 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by RMMI individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
06. Sep 19 Buy Earl Connors Individual 05. Sep 19 06. Sep 19 1,000 CA$0.69 CA$648
05. Sep 19 Buy Earl Connors Individual 04. Sep 19 04. Sep 19 500 CA$0.70 CA$350
03. Sep 19 Buy Earl Connors Individual 30. Aug 19 30. Aug 19 5,500 CA$0.70 CA$3,850
24. Sep 18 Buy David Guebert Individual 24. Sep 18 24. Sep 18 2,000 CA$2.50 CA$5,000
24. Sep 18 Buy John Fairfield Individual 24. Sep 18 24. Sep 18 2,000 CA$2.50 CA$5,000
24. Sep 18 Buy Earl Connors Individual 24. Sep 18 24. Sep 18 2,000 CA$2.50 CA$5,000
24. Sep 18 Buy Marc Staniloff Individual 24. Sep 18 24. Sep 18 2,000 CA$2.50 CA$5,000
24. Sep 18 Buy Peter Cheung Individual 24. Sep 18 24. Sep 18 2,000 CA$2.50 CA$5,000
24. Sep 18 Buy Eugene Chen Individual 24. Sep 18 24. Sep 18 2,000 CA$2.50 CA$5,000
X
Management checks
We assess RMMI's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. RMMI has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RMMI News

Simply Wall St News

What Type Of Shareholder Owns RMMI Corp.'s (CNSX:RMMI)?

See our latest analysis for RMMI CNSX:RMMI Ownership Summary, August 1st 2019 What Does The Lack Of Institutional Ownership Tell Us About RMMI? … Alternatively, there might be something about the company that has kept institutional investors away. … Insider Ownership Of RMMI While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

RMMI Company Info

Description

RMMI Corp., a development stage company, focuses on the cultivation, production, and sale of medical marijuana products in various forms. The company, through its subsidiary, Rocky Mountain Marijuana Inc., intends to produce cannabis oils. RMMI Corp. was incorporated in 2018 and is headquartered in Calgary, Canada.

Details
Name: RMMI Corp.
RMMI
Exchange: CNSX
Founded: 2018
CA$8,010,800
13,577,628
Website: http://www.rmmi.ca
Address: RMMI Corp.
639 – 5th Avenue SW,
Suite 1050,
Calgary,
Alberta, T2P 0M9,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX RMMI Common Shares Canadian National Stock Exchange CA CAD 25. Sep 2018
Number of employees
Current staff
Staff numbers
4
RMMI employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/20 01:33
End of day share price update: 2019/09/13 00:00
Last earnings filing: 2019/08/27
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.